

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VENTUREPHARM LABORATORIES LIMITED

萬全科技藥業有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code:8225)

HOLDING ANNOUNCEMENT

Reference is made to the meeting (the “Board meeting”) of the board (the “Board”) of directors (the “directors”) of Venturepharm Laboratories Limited (the “Company”) , As the result of the delay of the publication of the audited consolidated financial results of the company and its subsidiaries for the year ended 31 December 2011, trading in the securities of the company on the Stock Exchange has been suspended from 9:00 a.m. on 2 April 2012, and the Board was also delayed.

As the company need more time to complete the auditing work, which specifically includes the following: accounting treatment of Convertible Bonds, going concern assessment, impairment of receivables, and impairment of inventories. The company and auditors of the company will complete the auditing work as soon as possible, so as to resume the trading in the securities of the company on the Stock Exchange.

Trading in the securities of the company on the Stock Exchange will remain suspended until the release of an announcement relating to the publication of its annual results for the year 2011, first quarterly results , interim results , third quarterly results for the year 2012 and dispatch of its annual report for the year 2011, its first quarterly report, interim report, third quarterly report for the year 2012 .

By order of the Board

Venturepharm Laboratories Limited
William Xia Guo
Chairman

Beijing, the PRC, 7 February 2013

** For identification purpose only*

As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Li Jin Liang and Dr. Nathan Xin Zhang; and three independent non-executive directors, being Dr. Zhang Jing An, Mr. Paul Contomichalos and Dr. Wu Shou Yuan.

This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the Company’s website at www.venturepharm.com.